FDA approves vepdegestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer

Trial

VERITAC-2

Drug

Veppanu (vepdegestrant) · Proteolysis-targeting chimera estrogen receptor degrader

Condition

Breast